BBSC - ETF AI Analysis
Top Page
JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC)
BBSC, the JPMorgan BetaBuilders U.S. Small Cap Equity ETF, has a solid overall rating that reflects a mix of promising growth stories and some higher-risk names in the small-cap space. Strong contributors like Corcept Therapeutics, Moog, and SM Energy support the fund’s quality through solid financial health, growth in key sectors, and positive outlooks, while weaker holdings such as Twist Bioscience, with its profitability and cash flow challenges and bearish technical signals, may hold the rating back. The main risk factor is the ETF’s focus on smaller companies, where issues like high valuations, leverage, and lack of current profitability can make performance more volatile.
BBSC vs. SPDR S&P 500 ETF (SPY)
- AUM
- 751.21M
- Region
- North America
- Expense Ratio
- 0.09%
- Beta
- 1.07
- Issuer
- JPMorgan
- Inception Date
- Nov 16, 2020
- Dividend Yield
- 1.06%
- Asset Class
- Equity
- Index Tracked
- Morningstar US Small Cap Target Market Exposure Extended Index
BBSC Summary
BBSC is the JPMorgan BetaBuilders U.S. Small Cap Equity ETF, which follows the Morningstar US Small Cap Target Market Exposure Extended Index. It invests in many smaller U.S. companies across technology, health care, finance, and more, giving you broad exposure to the small‑cap part of the market. Well-known holdings include Semtech and Elastic, along with other growing niche businesses. Someone might invest in BBSC to seek long-term growth and diversify beyond large, familiar companies. A key risk is that small-cap stocks can be more volatile, so the ETF’s value can rise and fall sharply with changes in the market and the economy.
How much will it cost me?
This ETF has an annual expense ratio of 0.09%, which means you’ll pay about $0.90 per year for every $1,000 invested. That’s lower than the average ETF cost because it’s a passively managed fund that tracks an index rather than paying managers to pick individual stocks.
What would affect this ETF?
BBSC could benefit from strong U.S. economic growth, rising demand for technology and health care, and a healthy environment for small businesses, which often thrive when borrowing is affordable and consumer spending is solid. On the downside, higher interest rates, an economic slowdown in the U.S., or tighter regulations affecting tech, health care, or financial companies could hurt small-cap stocks and make this ETF more volatile.
BBSC Top 10 Holdings
BBSC is leaning into U.S. small-cap growth stories, with a clear tilt toward tech and health care names that can swing performance quickly. Twist Bioscience and Elastic have been rising over the past few months, helping drive returns, while Semtech and Moog show more mixed, sometimes lagging action that can tug the fund back. Health-focused plays like BrightSpring and Corcept add defensive growth but have had choppier, more volatile moves. With all holdings U.S.-based and no single stock dominating, the fund spreads its bets across many smaller innovators rather than one star performer.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 SMTC | Semtech | 0.56% | $4.13M | $11.89B | 87.85% | 69Neutral |
 FROG | JFrog | 0.42% | $3.12M | $11.64B | 100.83% | 73Outperform |
 MOG.A | Moog | 0.40% | $2.98M | $11.10B | 68.24% | 73Outperform |
 AHR | American Healthcare REIT, Inc. | 0.40% | $2.98M | $11.75B | 18.15% | 64Neutral |
 TWST | Twist Bioscience | 0.43% | $3.17M | $10.06B | 390.15% | 43Neutral |
 SM | SM Energy | 0.39% | $2.86M | $9.60B | 96.59% | 72Outperform |
 ESTC | Elastic | 0.37% | $2.75M | $10.31B | 10.06% | 65Neutral |
 BTSG | BrightSpring Health Services, Inc. | 0.36% | $2.71M | $13.24B | 104.00% | 67Neutral |
 CORT | Corcept Therapeutics | 0.35% | $2.57M | $8.77B | 12.26% | 76Outperform |
BBSC Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBSC, the sentiment is Neutral. The current price of 85.90 is above the 20-day moving average (MA) of 85.23, below the 50-day MA of 86.90, and above the 200-day MA of 84.12, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 50.45 is Neutral, neither overbought nor oversold. The STOCH value of 87.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BBSC.
BBSC Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| BBSC | $85.90 | $92.00(7.10% Upside) | $751.21M | 0.09% | 64Neutral |
 SFLO | $40.04 | $48.60(21.38% Upside) | $890.06M | 0.49% | 68Neutral |
 OUSM | $48.59 | $54.63(12.43% Upside) | $802.82M | 0.48% | 72Outperform |
 JHSC | $47.31 | $57.01(20.50% Upside) | $703.14M | 0.42% | 67Neutral |
 EES | $66.16 | $80.43(21.57% Upside) | $697.59M | 0.38% | 67Neutral |
 SMDV | $74.27 | $83.47(12.39% Upside) | $664.61M | 0.40% | 69Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BBSC | JPMorgan BetaBuilders U.S. Small Cap Equity ETF | 85.90 | 11.75 | 15.84% | |
| SFLO | VictoryShares Small Cap Free Cash Flow ETF | 40.04 | 11.66 | 41.10% | |
| OUSM | OShares U.S. Small-Cap Quality Dividend ETF | 48.59 | 5.99 | 14.06% | |
| JHSC | John Hancock Multifactor Small Cap ETF | 47.31 | 6.22 | 15.13% | |
| EES | WisdomTree U.S. SmallCap Fund | 66.16 | 11.96 | 22.08% | |
| SMDV | ProShares Russell 2000 Dividend Growers ETF | 74.27 | 10.66 | 16.75% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.